Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **combination allergenic extract biologic** composed of non-standardized pollen extracts from *Taraxacum officinale* (dandelion), *Helianthus annuus* (sunflower), and *Leucanthemum vulgare* (daisy). It has been manufactured and distributed by Greer Laboratories and is used in allergy practice for **skin test diagnosis** and **allergen immunotherapy** in patients with clinically relevant sensitization to these pollens. Its pharmacologic effect is immunologic rather than receptor-selective: diagnostically, it is intended to detect allergen-specific immediate hypersensitivity, and therapeutically, repeated exposure is intended to modulate IgE-mediated allergic responses and reduce allergen-induced symptoms in appropriately selected patients. The product was initially approved in the United States in 1968 as part of the allergenic extract category.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on taraxacum officinale pollen + helianthus annuus pollen + leucanthemum vulgare pollen.